Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 14;9:244. doi: 10.1038/s41420-023-01548-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — A The schematic diagram of SMASh-mediated ZHX1 degradation. B, C The protein (B) and mRNA (C) expression level of Zhx1 with the treatment of DAV in distinct concentrations (0, 0.5, 1, 1.5, and 2 μM). D A schematic diagram to represent the treatment timing and sample harvest during the SMASh-mediated ZHX1 knockdown. E The protein level of Zhx1 in the indicated days (D2, D4, D6, and D8) of cardiomyocyte differentiation after DAV treatment at different days (D0–D8, D0–D2, D2–D4, D4–D6, and D6–D8). F The expression of cardiomyocyte markers with the treatment of DAV (1 μM) at different days of cardiomyocyte differentiation. G The western blot results for the expression of cTNT and α-Actinin at day 8 of cardiomyocyte differentiation after DAV treatment (1 μM) at different days of cardiomyocyte differentiation. H The expression of cTNT protein with DAV treatment (1 μM) at different days of cardiomyocyte differentiation through immunofluorescent staining. Scale bar, 100 μm. Data are presented as the mean ± SEM (n = 3). The statistical significance is performed according to a two-way analysis of variance (ANOVA) followed by Bonferroni’s post hoc. *p < 0.05, **p < 0.01, and ***p < 0.001 versus Ctrl.